Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
265
resultados
Última actualización
25/08/2026 [06:52:00]
Resultados 175 a 200 de 265
Resumen de: WO2026170199A2
The present disclosure provides therapeutic matrix inverse targeting (MINT) nanoparticle including a MINT nanoparticle and a therapeutic material encapsulated in the MINT nanoparticle. The MINT nanoparticle includes a biocompatible polymer and an anionic coating. The disclosure further provides compositions including such a nanoparticle and methods of making such a nanoparticle or compositions. The disclosure further provides a method of treating an articular cartilage disease characterized by a decrease in glycosaminoglycan in extracellular matrix of articular cartilage using such a nanoparticle or composition.
Resumen de: WO2026167555A1
The present disclosure relates to a senescence-associated beta-galactosidase (SA-β-Gal) degradable polymeric nanoparticle, formulations, methods of producing said nanoparticle and uses in senotherapy. Said nanoparticle is capable of precisely and efficiently deliver and release a senotherapeutic active ingredient, namely a senolytic active ingredient, in organ-specific senescent cells, particularly the senescent liver cells, increasing the senotherapeutic index of the senolytic active ingredient and inducing apoptosis in senescent cells overexpressing SA-β-Gal.
Resumen de: WO2026169706A1
The disclosure relates to nanoconjugates and uses thereof. Specifically, the disclosure provides nanoconjugates comprising a biodegradable polymeric backbone conjugated to a blood-brain barrier penetrating peptide and an immunotherapeutic agent, and uses thereof for treating cancers of the central nervous system.
Resumen de: WO2026169105A1
The present invention relates to a pharmaceutical composition for preventing or treating diabetes comprising nanovesicles derived from Jerusalem artichoke (Helianthus tuberosus) as an active ingredient. The nanovesicles derived from Jerusalem artichoke exhibit a blood sugar reduction effect and a collagen synthesis inhibition effect, which are confirmed to be superior to those of Jerusalem artichoke extract, and thus the composition can be effectively utilized as a composition for preventing, treating or improving diabetes.
Resumen de: WO2026169809A1
Provided herein are methods of preventing and/or treating vesicant agent induced ocular injury. The methods comprise treating the eyes of a subject injured or at risk of being injured by a vesicant agent with dexamethasone sodium phosphate (DSP) loaded nanoparticles. In some aspects, the vesicant agent is mustard gas.
Resumen de: AU2024417973A1
This disclosure provides novel peptide hydrogels containing encapsulated nanoparticles comprising nucleic acid molecules (such as miRNA) that can undergo multiple gel-to-solution (gel-sol) and solution-to-gel (sol-gel) phase transitions, and their use, such as for controlled delivery of nucleic acid molecules to a subject. Also provided are novel peptides for use in disclosed peptide hydrogels.
Resumen de: WO2026169269A2
Provided herein are compositions comprising peptide-based nanoparticles. In some embodiments, the peptide-based nanoparticles each comprise a perfluorocarbon liquid core and a plurality of amphiphilic peptides surrounding the perfluorocarbon liquid core. In some embodiments, the amphiphilic peptides comprise a peptide analogue of Apolipoprotein A1. Also provided herein are methods of preparing any of the compositions described herein, as well as methods of treating atherosclerotic plaque formation using any of the composition described herein.
Resumen de: US20260232813A1
0000 A therapeutic nanoligomer composition includes at least a peptide nucleic acid (PNA), the at least a PNA including a sequence of nucleobases capable of interacting with a gene target in a target host and a polypeptide backbone attached to the sequence of nucleobases, the polypeptide backbone including a plurality of amino acid units, wherein the plurality of amino acid units includes at least a 2-N-aminoethylglycine unit; and a transport domain, the transport domain including a delivery nanoparticle and a cellular uptake domain (CUD) associated with the delivery nanoparticle, wherein the delivery nanoparticle is attached to the at least a PNA, and wherein the CUD includes a hydrophilic polymeric coating or one or more weakly charged surface groups.
Resumen de: US20260232836A1
The present disclosure relates, in part, to polypeptide-conjugated lipid nanoparticle (LNP) compositions, and methods of use thereof for brain-targeted delivery of therapeutic cargo. In another aspect, the disclosure provides methods for treating, preventing, and/or ameliorating disease and/or disorders of the brain (e.g., neurological disease and/or disorders).
Resumen de: US20260232838A1
Provided herein are synthetic melanin nanoparticles and methods useful for protecting cell-free reactions from prolonged solar and UV exposure.
Resumen de: WO2026169723A1
The present disclosure provides, among other things, improved lipid nanoparticles and improved methods of making lipid nanoparticles.
Resumen de: US20260232806A1
0000 Aspects describe nanoparticle-delivered adenyl cyclase activators (e.g., forskolin via LCMSN) to induce sWAT browning, enhancing thermogenesis for wound healing and cold injury protection. Applications include chronic wounds, diabetic ulcers, burns, frostbite, and hypothermia via subcutaneous or transdermal routes, with demonstrated acceleration of closure, reduced inflammation/necrosis, and improved angiogenesis/ECM remodeling in frostbite models.
Resumen de: WO2026166986A1
The present disclosure provides a compound of formula I: I or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions and suspensions comprising the compound of formula I, as well as uses thereof.
Resumen de: US20260234104A1
0000 A cationic lipid containing a disulfide bond of Formula (1), wherein, —S—S— is a disulfide bond; L<1 >and L<2 >are each independently a degradable divalent linking group, X<1 >and X<2 >are each independently an acyclic divalent linking group containing a tertiary amine group; G<1 >and G<2 >are each independently a linking bond or a trivalent branching group; when G<1 >is a linking bond, k1 is 1; when G<1 >is a trivalent branching group, k1 is 2; when G<2 >is a linking bond, k1 is 1; when G<2 >is a trivalent branching group, k2 is 2; R<1 >and R<2 >are each independently a substituted or unsubstituted C<5-30 >hydrocarbon group or C<5-30 >hydrocarbon derivative residue. The lipid composition prepared with the cationic lipid can more effectively exert the therapeutic effect of the LNP-nucleic acid pharmaceutical composition formulation, thereby improving immunological or therapeutic outcomes.
0000
Resumen de: WO2026168562A1
Problem To provide a bubble preparation capable of significantly suppressing a tumor and efficiently delivering a drug or the like to a site such as a tumor when used together with low-intensity therapeutic ultrasound. Solution A bubble preparation which exhibits a tumor suppressing effect when low-intensity therapeutic ultrasound is applied to the bubble preparation, the bubble preparation being characterized by comprising a coating film, which comprises a lipid, and a gas enclosed in the lumen of the coating film, wherein the coating film is an anionic lipid containing at least distearoylphosphatidylcholine (DSPC) and distearoylphosphatidylglycerol (DSPG), and the gas contains at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas.
Resumen de: WO2026169218A1
The present invention is a development of a vaccine formulation or a vaccine composition for inducing antigen-specific cells to generate immunity for resistance against Mycobacterium tuberculosis, comprising Bacillus Calmette-Guérin (BCG), ESAT-6 protein (ESAT-6) encapsulated with a nanoparticle-type carrier, and a STING ligand, wherein the BCG, the ESAT- 6 protein encapsulated with the nanoparticle-type carrier, and the STING ligand are physically and/or chemically combined, with a mass ratio of ESAT-6 to the STING ligand being in a range of 4-10 : 1, and wherein the vaccine composition according to the present invention is administered by a prime-pool strategy for preventing pulmonary tuberculosis infection.
Resumen de: WO2025027089A1
The present disclosure provides a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula I, as well as uses thereof.
Resumen de: WO2025024704A1
The present disclosure relates to polynucleotides comprising (a) a first region encoding a payload and (b) a second region comprising an immune cell detargeting sensor (e.g., a spleen detargeting sensor). Upon recognition of the marker by the sensor, the expression of the encoded payload is reduced or inhibited. Also provided herein are replicons, nanoparticles, synthetic circuits, pharmaceutical compositions comprising such polynucleotides. Methods of using the polynucleotides, replicons, synthetic circuits, nanoparticles, and pharmaceutical compositions are also provided.
Resumen de: AU2026208137A1
A method of producing lipid-encapsulated RNA nanoparticles includes flowing an aqueous solution comprising an RNA through a 1st tube having a first inner diameter (ID); the RNA comprises from about 6,000 to about 13,000 nucleotides; flowing an ethanol solution comprising lipids through a 2nd tube having a second inner diameter (ID), at a flow rate of about 0.2 to about 1 times relative to the aqueous solution through the 1st tube, the lipids comprise a cationic lipid; and mixing the ethanol solution with the aqueous solution; the first ID and second ID and flow rates through the 1st tube and 2nd tube are selected to produce a shear force sufficiently low to preserve the integrity of the RNA; the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about ethanol, the lipid-encapsulated RNA nanoparticles having a bilayer structure. ul u l
Resumen de: AU2026208121A1
Abstract Compositions and methods comprising pulmonary surfactant (PS)-biomimetic nanoparticles are disclosed. In particular, the disclosure relates to a composition comprising a negatively charged nanoparticle having an average size of 200 to 400 nm and comprising a plurality of pulmonary surfactant-biomimetic molecules, and one or more cargo molecules enveloped by the nanoparticle, wherein the cargo molecule has a molecular weight of up to 1200 Da. Abstract 40x ** wo 2021/071823 Perth Body weight change (%) Perth+PS-GAMP IgG titer Log10 = -5 -2.0 -10 SUBSTITUTE SHEET (RULE 26) Days post immunization Days post immunization PBS Perth GAMP Perth Michigan ** HAI titer PBS Perth+PS. Perth .GAMP PBS Perth+PS. Perth .GAMP PCT/US2020/054377 FIGS. 37A-37E ul u l e m p e r a t u r e h a n g e ( ° ) e r t h + - ( ) Days post immunization Days post immunization e r t h t i t e r t i t e r e r t h -
Resumen de: US20260234115A1
0000 The present disclosure provides lipid compounds and compositions (e.g., lipid nanoparticle (LNP) compositions) comprising lipid compounds of the present disclosure. The present disclosure provides methods of delivering an active agent (e.g., polynucleotide) to a cell or tissue in a subject, preferably an extrahepatic cell or tissue, comprising administering to the subject an effective amount of a lipid nanoparticle of the present disclosure, wherein the lipid nanoparticle comprises lipid compounds of the present disclosure and the active agent (e.g., polynucleotide).
Resumen de: US20260232849A1
0000 Compositions, methods, and kits relating to substantially monodisperse, ultrasound targeted nanobubble compositions are disclosed. The nanobubble compositions comprise a hollow core containing at least one gas and a polymer shell encircling the hollow core. Methods of producing the substantially monodisperse nanobubble compositions using an ultrasound shearing-based fabrication method are disclosed. Methods of using the nanobubble compositions are also disclosed.
Resumen de: WO2025000039A1
Disclosed herein is a bioactive polymer for forming a solution and/or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA/HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA/HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.
Resumen de: US20260232587A1
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent.
Nº publicación: AU2026206234A1 13/08/2026
Solicitante:
SOLIGENIX INC
UNIV OF HAWAII
Soligenix, Inc.
University of Hawaii
Resumen de: AU2026206234A1
Abstract Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovrus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use. Also disclosed is a vaccine composition comprising at least two antigens, wherein each antigen is specific to a different genus of filovirus and which also comprises at least one nano-emulsion adjuvant. Abstract
BOPI
Sede Electrónica
